NCT03986606: A Study of PSB205 in Subjects With Advanced Solid Tumors

NCT03986606
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the dose escalation phase (not the expansion phase); Patients must have received 1+ prior lines of therapy
Exclusions: Patients with untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression; Stable metastases are permitted- see trial for details; Patients with prior treatment with a CTLA-4 inhibitor in combination with a PD-1 or PD-L1 inhibitor
https://ClinicalTrials.gov/show/NCT03986606

Comments are closed.

Up ↑